Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy
Open Access
- 15 March 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 56 (5) , 1719-1729
Abstract
Glycogen storage disease type Ia (GSD-Ia), which is characterized by impaired glucose homeostasis and chronic risk of hepatocellular adenoma (HCA), is caused by deficiencies in the endoplasmic reticulum (ER)-associated glucose-6-phosphatase-α (G6Pase-α or G6PC) that hydrolyzes glucose-6-phosphate (G6P) to glucose. G6Pase-α activity depends on the G6P transporter (G6PT) that translocates G6P from the cytoplasm into the ER lumen. The functional coupling of G6Pase-α and G6PT maintains interprandial glucose homeostasis. We have shown previously that gene therapy mediated by AAV-GPE, an adeno-associated virus (AAV) vector expressing G6Pase-α directed by the human G6PC promoter/enhancer (GPE), completely normalizes hepatic G6Pase-α deficiency in GSD-Ia (G6pc−/−) mice for at least 24 weeks. However, a recent study showed that within 78 weeks of gene deletion, all mice lacking G6Pase-α in the liver develop HCA. We now show that gene therapy mediated by AAV-GPE maintains efficacy for at least 70-90 weeks for mice expressing more than 3% of wild-type hepatic G6Pase-α activity. The treated mice displayed normal hepatic fat storage, had normal blood metabolite and glucose tolerance profiles, had reduced fasting blood insulin levels, maintained normoglycemia over a 24-hour fast, and had no evidence of hepatic abnormalities. After a 24-hour fast, hepatic G6PT messenger RNA levels in G6pc−/− mice receiving gene therapy were markedly increased. Because G6PT transport is the rate-limiting step in microsomal G6P metabolism, this may explain why the treated G6pc−/− mice could sustain prolonged fasts. The low fasting blood insulin levels and lack of hepatic steatosis may explain the absence of HCA. Conclusion : These results confirm that AAV-GPE–mediated gene transfer corrects hepatic G6Pase-α deficiency in murine GSD-Ia and prevents chronic HCA formation.Keywords
This publication has 28 references indexed in Scilit:
- Recombinant AAV-directed gene therapy for type I glycogen storage diseasesExpert Opinion on Biological Therapy, 2011
- Insulin signaling to hepatic lipid metabolism in health and diseaseCritical Reviews in Biochemistry and Molecular Biology, 2011
- Liver glucokinase: An overview on the regulatorymechanisms of its activityIUBMB Life, 2011
- Complete Normalization of Hepatic G6PC Deficiency in Murine Glycogen Storage Disease Type Ia Using Gene TherapyMolecular Therapy, 2010
- The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblastsJournal of Clinical Investigation, 2009
- Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type IaJournal of Hepatology, 2008
- Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenesJournal of Clinical Investigation, 2005
- Hepatocellular carcinoma in glycogen storage disease type Ia: A case seriesJournal of Inherited Metabolic Disease, 2004
- Mechanisms of blood glucose homeostasisJournal of Inherited Metabolic Disease, 1990
- Cornstarch Therapy in Type I Glycogen-Storage DiseaseNew England Journal of Medicine, 1984